AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18154126 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (TTD-60-110 Gy)
Number of subjects: 174
Study 15220228 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthening (ATL) and total contact casting (TCC)
Number of subjects: 28
Study 15220228 — intervention group
Group type: COMPARATOR
Intervention: Total contact casting (TCC)
Number of subjects: 28
Study 11587240 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care outpatient treatment program
Number of subjects: 78
Study 11587240 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration of heart failure and low blood hemoglobin concentration
Number of subjects: 78
Study 11587240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MMSE score
Number of subjects: 78
Study 10446036 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention through community dental care including annual inquiries about smoking, showing photographs of harmful effects, self-examination with a mirror, and counseling based on smoking habits.
Number of subjects: 2586
Study 10446036 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (no specific intervention details provided).
Number of subjects: 2586
Study 7872284 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (1 g/day)
Number of subjects: 193
Study 7872284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 2143129 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion at 0.25 micrograms/min
Number of subjects: 17
Study 2143129 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion at 2.0 micrograms/min
Number of subjects: 17
Study 2143129 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ANF concentrations between young and elderly subjects
Number of subjects: 17
Study 2143129 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of changes in systolic blood pressure and mean arterial pressure for higher ANF levels in elderly
Number of subjects: 17
Study 332184 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 gm aspirin daily for 5 days
Number of subjects: 40
Study 332184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31188696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice (TCJ)
Number of subjects: 10
Study 31188696 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 29342509 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination format (numbers + IA + BS)
Number of subjects: 0
Study 29342509 — intervention group
Group type: COMPARATOR
Intervention: Balance Scales (BS)
Number of subjects: 0
Study 29342509 — intervention group
Group type: COMPARATOR
Intervention: Numbers-only format
Number of subjects: 0
Study 29342509 — intervention group
Group type: COMPARATOR
Intervention: Icon Array (IA) alone
Number of subjects: 0
Study 29342509 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon Array (IA) with or without BS
Number of subjects: 0
Study 26403252 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based resource providing personalized health history, late effects information, and resources via a password-protected Web portal
Number of subjects: 52
Study 26403252 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (physician counseling) only
Number of subjects: 52
Study 24994869 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free eye drops (0.1% sodium hyaluronate and 0.1% fluorometholone for the first month; 0.1% sodium hyaluronate and 0.05% cyclosporine for the second and third months)
Number of subjects: 100
Study 24994869 — intervention group
Group type: COMPARATOR
Intervention: Preserved eye drops
Number of subjects: 100
Study 24994869 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free eye drops
Number of subjects: 100
Study 22225814 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 90
Study 22225814 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose aciclovir (400 mg twice daily)
Number of subjects: 90
Study 22225814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aciclovir (800 mg three times daily)
Number of subjects: 90
Study 22225814 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose valaciclovir (500 mg daily)
Number of subjects: 90
Study 22225814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose valaciclovir (1 g three times daily)
Number of subjects: 90
Study 22225814 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose valaciclovir
Number of subjects: 90
Study 20551816 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative incentive spirometry (group PR)
Number of subjects: 50
Study 20551816 — intervention group
Group type: COMPARATOR
Intervention: Postoperative incentive spirometry (group PO)
Number of subjects: 50
Study 18492750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) oral (os)
Number of subjects: 32
Study 18492750 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol (D2) oral (os)
Number of subjects: 32
Study 18492750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) intramuscular (im)
Number of subjects: 32
Study 18492750 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol (D2) intramuscular (im)
Number of subjects: 32
Study 18492750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3)
Number of subjects: 32
Study 18492750 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 32
Study 16171713 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated vasodilation (FMD)
Number of subjects: 66
Study 11578300 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meal stimulation test (563 kcal)
Number of subjects: 50
Study 9753533 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Competency Rating Scale (PCRS) administered to TBI patients
Number of subjects: 30
Study 9753533 — intervention group
Group type: COMPARATOR
Intervention: Patient Competency Rating Scale (PCRS) administered to controls
Number of subjects: 30
Study 9753533 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference scores (PCRS-P minus PCRS-R)
Number of subjects: 30
Study 9753533 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Glasgow Coma Scale (GCS) scores and posttraumatic amnesia (PTA) estimates
Number of subjects: 30
Study 8164820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 1 mg/kg (young controls)
Number of subjects: 35
Study 8164820 — intervention group
Group type: COMPARATOR
Intervention: Invalid cue performance (AD patients)
Number of subjects: 35
Study 8164820 — intervention group
Group type: COMPARATOR
Intervention: Valid cue performance (all groups)
Number of subjects: 35
Study 8164820 — intervention group
Group type: COMPARATOR
Intervention: Invalid cue performance (all groups)
Number of subjects: 35
Study 3047336 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen priming for three days before and on the day of chemotherapy
Number of subjects: 85
Study 3047336 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 85
Study 3047336 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen priming
Number of subjects: 85
Study 2043503 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary letter sent to patients after consultations (Experimental group, N = 23)
Number of subjects: 52
Study 2043503 — intervention group
Group type: COMPARATOR
Intervention: Control group (letter to GP only, N = 29)
Number of subjects: 52
Study 794558 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (25-(OH)D3) 25 to 200 mug/day
Number of subjects: 14
Study 794558 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (25-(OH)D3) 25 to 50 mug/day with calcium supplementation (0.5 to 1.5 g/day)
Number of subjects: 14
Study 794558 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation alone (0.5 to 0.75 g/day)
Number of subjects: 14
Study 794558 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (25-(OH)D3)
Number of subjects: 14
Study 30031748 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted neuromuscular exercises for 12 weeks
Number of subjects: 75
Study 30031748 — intervention group
Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 75
Study 27376544 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (260 mJ/4 Hz) re‐wetting with chlorhexidine
Number of subjects: 20
Study 27376544 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (260 mJ/4 Hz) re‐wetting with deionized water
Number of subjects: 20
Study 27376544 — intervention group
Group type: COMPARATOR
Intervention: Conventional method re‐wetting with chlorhexidine
Number of subjects: 20
Study 27376544 — intervention group
Group type: COMPARATOR
Intervention: Conventional method re‐wetting with deionized water
Number of subjects: 20
Study 24831043 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week video plus educational booklet intervention
Number of subjects: 92
Study 24831043 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 92
Study 23561712 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily for 3 days
Number of subjects: 60
Study 23561712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21364527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural group treatment (eight sessions)
Number of subjects: 98
Study 21364527 — intervention group
Group type: COMPARATOR
Intervention: Waiting‐list control group
Number of subjects: 98
Study 19630485 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nephrostomy tube placement after multitract PCNL (Group A)
Number of subjects: 192
Study 19630485 — intervention group
Group type: COMPARATOR
Intervention: Multiple nephrostomy tubes (Group B)
Number of subjects: 192
Study 17374657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (42 g)
Number of subjects: 30
Study 17374657 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (1 g)
Number of subjects: 30
Study 15325832 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 18325
Study 15325832 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 18325
Study 15325832 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen 800 mg three times daily
Number of subjects: 18325
Study 11251007 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (10 microg/kg IV) + Dexamethasone (20 mg PO)
Number of subjects: 351
Study 11251007 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (10 microg/kg IV) + MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Number of subjects: 351
Study 11251007 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-869 (400 mg PO evening before and pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Number of subjects: 351
Study 11251007 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Number of subjects: 351
Study 9891256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention (8-week duration)
Number of subjects: 0
Study 9891256 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 8281644 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic blockade using 0.04 mg/kg atropine and 0.2 mg/kg propranolol
Number of subjects: 8
Study 2660561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times a day
Number of subjects: 70
Study 2660561 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sucralfate 1 g three times a day and 400 mg cimetidine at night
Number of subjects: 70
Study 2660561 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate maintenance 2 g daily
Number of subjects: 70
Study 2660561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30408282 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual stepped-care stress-management intervention (CBT techniques, completed within 26 weeks)
Number of subjects: 291
Study 30408282 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2 intervention (additional 3-8 sessions for patients with significant stress)
Number of subjects: 291
Study 30408282 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not report clinically significant stress levels participated in only one counseling session)
Number of subjects: 291
Study 27568306 — intervention group
Group type: COMPARATOR
Intervention: Incisal anesthesia
Number of subjects: 45
Study 27568306 — intervention group
Group type: COMPARATOR
Intervention: Block anesthesia
Number of subjects: 45
Study 27568306 — intervention group
Group type: COMPARATOR
Intervention: Mucosal anesthesia
Number of subjects: 45
Study 27568306 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference group
Number of subjects: 45
Study 25873044 — intervention group
Group type: EXPERIMENTAL
Intervention: HBPTM plus individualized, culturally‐tailored, telephone‐based NCM
Number of subjects: 450
Study 25873044 — intervention group
Group type: COMPARATOR
Intervention: HBPTM alone
Number of subjects: 450
Study 23221809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cardiac rehabilitation program
Number of subjects: 236
Study 23221809 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 236
Study 23221809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR programs
Number of subjects: 236
Study 21552054 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate (7% sucralfate ointment applied twice daily for 6 weeks)
Number of subjects: 80
Study 21552054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (petroleum jelly ointment applied twice daily for 6 weeks)
Number of subjects: 80
Study 21552054 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate
Number of subjects: 80
Study 21552054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19803236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with TDP irradiation
Number of subjects: 60
Study 19803236 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal steaming and washing therapy
Number of subjects: 60
Study 19803236 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (Vitamin B1, Vitamin B12, compound Vitamin B, small splint for wrist protection)
Number of subjects: 60
Study 16908790 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/d)
Number of subjects: 594
Study 16908790 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-containing regimen (conjugated equine estrogens and medroxyprogesterone acetate or micronized progestin)
Number of subjects: 594
Study 16908790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 15160443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg (E20)
Number of subjects: 749
Study 15160443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg (E10)
Number of subjects: 749
Study 15160443 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (L10)
Number of subjects: 749
Study 15160443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 749
Study 11407965 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Music (GIM)
Number of subjects: 8
Study 11407965 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 8
Study 9387112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 80
Study 9387112 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120
Number of subjects: 80
Study 9387112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 80
Study 8186349 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg b.d.
Number of subjects: 318
Study 8186349 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 20 mg b.d.
Number of subjects: 318
Study 8186349 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 318
Study 3285836 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (200 mg/day)
Number of subjects: 10
Study 3285836 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (500 mg/day)
Number of subjects: 10
Study 31945015 — intervention group
Group type: EXPERIMENTAL
Intervention: BPZE1
Number of subjects: 12
Study 31945015 — intervention group
Group type: COMPARATOR
Intervention: aPV
Number of subjects: 12
Study 29570005 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Activity Supports You (lifestyle intervention)
Number of subjects: 25
Study 29570005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 28005003 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter sent from GP to parents/carers reminding about medication (n=70 practices)
Number of subjects: 142
Study 28005003 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 142
Study 24461364 — intervention group
Group type: COMPARATOR
Intervention: ACT group
Number of subjects: 82
Study 24461364 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG group
Number of subjects: 82
Study 22858176 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2a 180 μg SC
Number of subjects: 36
Study 22858176 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN alfa‐2a 90 μg IV
Number of subjects: 36
Study 19324346 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) 6-g bolus IV followed by 2 g/h baseline
Number of subjects: 42
Study 19324346 — intervention group
Group type: COMPARATOR
Intervention: Healthy nonpregnant women
Number of subjects: 42
Study 19324346 — intervention group
Group type: COMPARATOR
Intervention: Pregnant control women (HP)
Number of subjects: 42
Study 19324346 — intervention group
Group type: EXPERIMENTAL
Intervention: General health of infants born to preeclamptic mothers given MgSO4
Number of subjects: 42
Study 17868489 — intervention group
Group type: EXPERIMENTAL
Intervention: LoBAG30 diet (30% protein, 50% fat, 30% carbohydrate)
Number of subjects: 8
Study 17868489 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (15% protein, 30% fat, 55% carbohydrate)
Number of subjects: 8
Study 15766334 — intervention group
Group type: EXPERIMENTAL
Intervention: Apfel et al.'s scoring system
Number of subjects: 1388
Study 15766334 — intervention group
Group type: EXPERIMENTAL
Intervention: Koivuranta et al.'s scoring system
Number of subjects: 1388
Study 12495098 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infusion at 2 mL/hr for 48 hours plus PCA morphine
Number of subjects: 52
Study 12495098 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine only
Number of subjects: 52
Study 10622581 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) alone at standard dosage (3 MU t.i.w.) for 12 months
Number of subjects: 150
Study 10622581 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin as single therapy at standard dosage (15 mg/kg bodyweight in two divided doses daily)
Number of subjects: 150
Study 10622581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin in combination with interferon alpha at standard doses for 6-12 months
Number of subjects: 150
Study 7749168 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron) monotherapy
Number of subjects: 1050
Study 7749168 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban + dexamethasone
Number of subjects: 1050
Study 7749168 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban
Number of subjects: 1050
Study 7749168 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban + corticosteroid
Number of subjects: 1050
Study 2405323 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate alone (N = 23)
Number of subjects: 51
Study 2405323 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate plus tobramycin (N = 28)
Number of subjects: 51
Study 161170 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microgram ipratropium bromide (I)
Number of subjects: 8
Study 161170 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microgram fenoterol (F)
Number of subjects: 8
Study 161170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs in combination (IF)
Number of subjects: 8
Study 161170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study 31927026 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone 160 mg with 50 mL water, administered 2-8 hours before surgery
Number of subjects: 60
Study 31927026 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 31927026 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone group
Number of subjects: 60
Study 31927026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 31927026 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 30636701 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg methylcobalamin
Number of subjects: 373
Study 30636701 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg methylcobalamin
Number of subjects: 373
Study 30636701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 28502083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic optical coherence tomography (D‐OCT)
Number of subjects: 47
Study 27281727 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL interscalene nerve block
Number of subjects: 154
Study 27281727 — intervention group
Group type: COMPARATOR
Intervention: 40 mL interscalene nerve block
Number of subjects: 154
Study 24679400 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 24679400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 24679400 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended-release
Number of subjects: 1008
Study 21931122 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (IV or oral depending on site)
Number of subjects: 272
Study 21931122 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 272